|
Membership
Application |
| IMT Steering Committee Chairman: David Pendleton Dominic Smith Maureen Duffy Katherine
Frisbee Kim
Giordano Colleen Glynn Girish
Hagan David
LaPointe Tim
McCarthy Adrian
Nunn Patrick O'Day Michael
Reitermann Anwer
Rizvi Maarten de Jonge, PhD Fred Stuvek Ruth
Tesar Rodney
Thomason Thom Tulip Ex
Officio: R.
Edward Coleman, M.D. |
||
 |
||
The
Institute for Molecular Technologies
Bringing the benefits of molecular imaging into
focus.
Advanced molecular imaging modalities have made a dramatic difference for patients with cancer, cardiac disease and neurological disorders. Today, PET is covered by Medicare and many private payer organizations for all the leading cancers, as well as cardiac disease and epilepsy. Yet there is much more that molecular imaging can do to diagnose, stage and treat disease. Medicare coverage and reimbursement play a critical role in how these advanced modalities are implemented by the healthcare community.
The Institute for Molecular Technologies (IMT) educates healthcare professionals, policy makers and the public on the value of advanced molecular imaging, with a particular focus on PET and PET/CT. And while AMI provides the framework, IMT is a powerful institute with its own organization and governing structures. According to its Operating Guidelines,
IMT's purpose is to sponsor and promote educational efforts to medical and science professionals, patients and the public, Congress, and government agencies in support of molecular imaging, while promoting cooperation between AMI and other organizations with similar missions, e.g., the SNM and the Radiological Society of North America (RSNA), in pursuit of its purposes.
Membership Benefits > Membership Brochure >
National Oncologic PET RegistryTo learn more about the National Oncologic PET Registry visit the NOPR Web site at www.cancerPETregistry.org for more information.